| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2250-0068 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-195 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2006-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2008-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2008538302-A |
| titleOfInvention |
Bioactive stent for type II diabetic patients and method of use thereof |
| abstract |
The present invention relates to a biodegradable biocompatible polymer coupled with a bioligand that specifically captures endothelial cell precursors (PEC) from circulating blood and promotes the endogenous formation of healthy endothelium in type II diabetic patients. And based on the discovery that vascular stents or other implantable medical devices can be coated. In one embodiment, the bioligand is a peptide that specifically binds to an integrin receptor on PEC. The present invention also provides a method for promoting vascular healing in type II diabetic patients using such vascular stents and other implantable devices, for example after mechanical intervention. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016508752-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015232707-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013507217-A |
| priorityDate |
2005-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |